an exploratory study to evaluate a digital intervention to disrupt scratching in atopic dermatitis and psoriasis

Conditions: Psoriasis; Atopic Dermatitis

Summary: ct-100 is a platform that provides interactive, software based therapeutic components that may be used as part of a treatment in future software-based prescription digital therapeutics. one class of ct-100 components are digital neuro-activation and modulation (dinamo tm) components. dinamo components target key neural systems (including but not limited to systems related to sensory-, perceptual-, affective-, pain-, attention-, cognitive control, social- and self- processing) to optimally improve a participant's health.

ct-100 is a platform that provides interactive, software based therapeutic components that may be used as part of a treatment in future software-based prescription digital therapeutics. one class of ct-100 components are digital neuro-activation and modulation (dinamo tm) components. dinamo components target key neural systems (including but not limited to systems related to sensory-, perceptual-, affective-, pain-, attention-, cognitive control, social- and self- processing) to optimally improve a participant's health. the purpose of the proposed study is to evaluate initial effects of the dinamo component on measures of undesired behavior intensity and related outcomes in a variety of conditions, such as atopic dermatitis and psoriasis

Eligibility criteria:
inclusion criteria: * fluent in written and spoken english, confirmed by ability to read, understand and sign the informed consent form (icf). * lives in the united states. * aged 18 years or older. * itch nrs ≥ 4 during screening. * meets indication-specific inclusion criteria (see appendix 1), as reported by the study participant with adequate clinical documentation. (documentation to be provided to the study team upon request.) * has an active email address and is willing and able to receive and respond to email messages. * has access to an internet connection during the study duration. * willing and able to comply with the study protocol and assessments. * is the sole user of an iphone with an iphone operating system (os) 14 or later or a smartphone with an android os 10 or later for the duration of the study. * is willing and able to receive short message service (sms) text messages and notifications on their smartphone. exclusion criteria: * pregnant or planning to become pregnant. * visual, dexterity or cognitive deficit so severe that it precludes the use of an app-based, reaction-time-based activity per investigator judgment. * severe psychiatric disorder involving a history of psychosis (e.g., schizophrenia, bipolar disorder or severe personality disorders). * psychiatric hospitalization in the past 6 months. * participation in any research study (including studies on psychotherapy, mindfulness, cognitive training or pharmacological treatment) during the past 3 months. * initiation or change in primary-disease-specific medication within 30 days prior to entering the study. * self-reported substance-use disorder within the past 1 year. * currently experiencing a skin infection. * planning the introduction of new therapies (including studies on psychotherapy, mindfulness, cognitive training or pharmacological treatment) during the 7-week study period. * anticipating a change in current pharmacological or psychotherapy treatment regimen during the 7-week study period.

Keywords: itching dinamo